Evidence map›Paper›PMID 32237740›Full record

ArticleBiomacromolecules2020

3D-Printing of Structure-Controlled Antigen Nanoparticles for Vaccine Delivery.

Akihiro Nishiguchi, Fumiaki Shima, Smriti Singh, Mitsuru Akashi, Martin Moeller

Abstract read
In one paragraph

Article in Biomacromolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  3. Rising role of 3D-printing in delivery of therapeutics for infectious disease.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  4. Review
  5. Review
  6. 3D Printing in Development of Nanomedicines.Nanomaterials (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Akihiro NishiguchiDWI-Leibniz-Institute for Interactive Materials, RWTH Aachen University, Forckenbeckstrasse 50, D-52056 Aachen, Germany.ORCID 0000-0002-3160-6385
Fumiaki ShimaGraduate School of Frontier Biosciences, Osaka University, Yamadaoka 1-3, Suita 565-0871, Osaka, Japan.
Smriti SinghDWI-Leibniz-Institute for Interactive Materials, RWTH Aachen University, Forckenbeckstrasse 50, D-52056 Aachen, Germany.ORCID 0000-0002-2164-9912
Mitsuru AkashiGraduate School of Frontier Biosciences, Osaka University, Yamadaoka 1-3, Suita 565-0871, Osaka, Japan.
Martin MoellerDWI-Leibniz-Institute for Interactive Materials, RWTH Aachen University, Forckenbeckstrasse 50, D-52056 Aachen, Germany.ORCID 0000-0002-5955-4185

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted delivery of antigens to immune cells using micro/nanocarriers may serve as a therapeutic application for vaccination. However, synthetic carriers have potential drawbacks including cytotoxicity, low encapsulation efficiency of antigen, and lack of a morphological design, which limit the translation of the delivery system to clinical use. Here, we report a carrier-free and three-dimensional (3D)-shape-designed antigen nanoparticle by multiphoton lithography-based 3D-printing. This simple, versatile 3D-printing approach provides freedom for the precise design of particle shapes with a nanoscale resolution. Importantly, shape-designed antigen nanoparticles with distinct aspect ratios show shape-dependent immune responses. The 3D-printing approach for the rational design of nanomaterials with increasing safety, complexity, and efficacy offers an emerging platform to develop vaccine delivery systems and mechanistic understanding.

Indexed as

NanoparticlesVaccinesAntigensDrug Delivery SystemsPrinting, Three-DimensionalAntigensVaccines

Identifiers

PMID32237740
PMCPMC7434010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.